Stock ACURA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Acura Pharmaceuticals, Inc. OTC Bulletin Board

Equities

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Acura Pharmaceuticals, Inc.
Mar. 26 Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC CI
Mar. 14 Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K
PU
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
CI
Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K
PU
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note
CI
Acura Pharmaceuticals : New Financial Obligation - Form 8-K
PU
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors
CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets
CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03
CI
Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K
PU
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
CI
Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K
PU
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC
CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACUR Stock
  4. Stock
  5. News Acura Pharmaceuticals, Inc.